Pharmaceutical Technology® spoke with Krishna Kanumuri, CEO of Sai Life Sciences, about which trends from 2024 will carry over and impact the bio/pharma industry in 2025.
In the post-COVID world, pharmaceutical companies have been looking to reconfigure their supply chains and work with global partners, according to Krishna Kanumuri, CEO of Sai Life Sciences. “I think people are looking for the next-generation partners they need [for their] business, which is a challenge, both for providers as well as customers, because customers need to develop new relationships, need to get [these up to speed], and still need to deliver on their programs,” Kanumuri says.
“I think [the] pharma industry itself is looking at what their pipelines [will] look like going forward,” Kanumuri says. “If you look three, four years back, pharma was talking about gene therapy, cell therapy. But right now, thanks to GLP-1s [glucagon-like peptide-1], I think the three main modalities which are getting very exciting at this point are peptides, oligonucleotides, and ADCs [antibody drug conjugates], along with small molecules which seem to be back, and also the fact that all these modalities, about 80% of the work is actually small molecules.”
Click the video above to watch the full interview.
Krishna Kanumuri is CEO of Sai Life Sciences.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.